Bruce Bellande, PhD, was pleased to learn this month that regulators accepted the cache of materials he sent them as adequate demonstration of corporate separation.
Non-accredited commercial providers have nearly two years to comply with new medical education rules affecting their ability to jointly sponsor activities, regulators said yesterday.
Novartis' Tasigna (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec (imatinib).
GlaxoSmithKline and Tolerx, have announced a global collaboration deal worth up to $760 million to develop and commercialize otelixizumab (TRX4), a novel humanised anti-CD3 monoclonal antibody that has potential across a broad range of autoimmune and immune-mediated inflammatory diseases, including type 1 diabetes.
Advertise
For details on how to advertise in MM&M News Brief, please email Doreen Gates
To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.
All MM&M newsletters are sent from the domain "email.mmm-online.com". When configuring e-mail or spam filter rules, please
use this domain name.
Medical Marketing & Media Magazine
114 W. 26th Street 4th Floor
New York
N.Y. 10001
Phone: (646) 638-6000
Fax: (646) 638-6150 http://www.mmm-online.com/
You are subscribed as: %%EMAIL%%